NCT01585038View on ClinicalTrials.gov

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2014

Conditions
Cardiovascular Disease
Interventions
DRUG

Efavirenz

600mg orally every evening

DRUG

Rilpivirine

25mg orally once daily

Trial Locations (1)

46202

Indiana Clinical and Translational Sciences Institute, Indianapolis

All Listed Sponsors
collaborator

Janssen Services, LLC

INDUSTRY

lead

Indiana University

OTHER

NCT01585038 - Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress | Biotech Hunter | Biotech Hunter